Gender, Bladder Cancer Healthcare and Burden of COVID-19

References

• Chen L, Li Q, Zheng D, Jiang H, Wei Y, Zou L, et al. Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. N Engl J Med. 2020;382(25):e100. doi:10.1056/NEJMc2009226.
   PubMed Web of Science ®Google Scholar
• Worldometers. COVID-19 coronavirus pandemic. https://www.worldometers.info/coronavirus/
   Google Scholar
• Xie M, Chen Q. Insight into 2019 novel coronavirus—An updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020;94:119–124. doi:10.1016/j.ijid.2020.03.071.
   PubMed Web of Science ®Google Scholar
• Abdelrahman Z, Li M, Wang X. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses. Front Immunol. 2020;11:552909. doi:10.3389/fimmu.2020.552909.
   PubMed Web of Science ®Google Scholar
• Abbasi E, Mirzaei F, Tavilani H, Khodadadi I. Diabetes and COVID-19: mechanism of pneumonia, treatment strategy and vaccine. Metabol Open. 2021; 11:100122. doi:10.1016/j.metop.2021.100122.
   PubMedGoogle Scholar
• Ti LK, Ang LS, Foong TW, Ng BSW. What we do when a COVID-19 patient needs an operation: operating room preparation and guidance. Can J Anaesth. 2020;67(6):756–758. doi:10.1007/s12630-020-01617-4.
   PubMed Web of Science ®Google Scholar
• Teoh JY-C, Ong WLK, Gonzalez-Padilla D, Castellani D, Dubin JM, Esperto F, UroSoMe Working Group, et al. A global survey on the impact of COVID-19 on urological services. Eur Urol. 2020;78(2):265–275. doi:10.1016/j.eururo.2020.05.025.
   PubMed Web of Science ®Google Scholar
• Ellimoottil C, Skolarus T, Gettman M, Boxer R, Kutikov A, Lee BR, et al. Telemedicine in urology: state of the art. Urology. 2016;94:10–16. doi:10.1016/j.urology.2016.02.061.
   PubMedGoogle Scholar
• Lucero-Prisno DE, III Elhadi YAM, Modber MAA, Musa MB, Mohammed SEE, Hassan KF, et al. Drug shortage crisis in Sudan in times of COVID-19. Public Health Pract (Oxf)). 2020;1:100060. doi:10.1016/j.puhip.2020.100060.
   PubMedGoogle Scholar
• Heldwein FL, Loeb S, Wroclawski ML, Sridhar AN, Carneiro A, Lima FS, et al. A systematic review on guidelines and recommendations for urology standard of care during the COVID-19 pandemic. Eur Urol Focus. 2020;6(5):1070–1085. doi:10.1016/j.euf.2020.05.020.
   PubMedGoogle Scholar
• Perrotta F, Matera MG, Cazzola M, Bianco A. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? Respir Med. 2020;168:105996. doi:10.1016/j.rmed.2020.105996.
   PubMed Web of Science ®Google Scholar
• Groß S, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications. J Mol Cell Cardiol. 2020;144:47–53. doi:10.1016/j.yjmcc.2020.04.031.
   PubMed Web of Science ®Google Scholar
• Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020;6(1):1–4. doi:10.1038/s41421-020-0147-1.
   PubMed Web of Science ®Google Scholar
• Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19. ).J Pathol. 2020;251(3):228–248. doi:10.1002/path.5471.
   PubMed Web of Science ®Google Scholar
• Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211–212. doi:10.1016/j.dsx.2020.03.002.
   PubMed Web of Science ®Google Scholar
• Han Q, Lin Q, Jin S, You L. Coronavirus 2019-nCoV: a brief perspective from the front line. J Infect. 2020;80(4):373–377. doi:10.1016/j.jinf.2020.02.010.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. J Med Virol. 2020;92(6):568–576. doi:10.1002/jmv.25748.
   PubMed Web of Science ®Google Scholar
• Shanmugam C, Mohammed AR, Ravuri S, Luthra V, Rajagopal N, Karre S. COVID-2019–A comprehensive pathology insight. Pathol Res Pract. 2020;216(10):153222. doi:10.1016/j.prp.2020.153222.
   PubMed Web of Science ®Google Scholar
• Teoh JY-C, Yip TC-F, Lui GC-Y, Wong VW-S, Chow VC-Y, Ho TH-Y, et al. Risks of AKI and major adverse clinical outcomes in patients with severe acute respiratory syndrome or coronavirus disease 2019. JASN. 2021;32(4):961–971. doi:10.1681/ASN.2020071097.
   Web of Science ®Google Scholar
• Enikeev D, Taratkin M, Efetov S, Shlomina A, Boldyreva M, Galkina I, et al. Acute kidney injury in COVID-19: are kidneys the target or just collateral damage? A comprehensive assessment of viral RNA and AKI rate in patients with COVID-19. Curr Opin Urol. 2021;31(4):363–368. doi:10.1097/MOU.0000000000000901.
   PubMed Web of Science ®Google Scholar
• Chan VW-S, Chiu PK-F, Yee C-H, Yuan Y, Ng C-F, Teoh JY. C. A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions. World J Urol. 2021;39(9):3127–3138. doi:10.1007/s00345-020-03246-4.
   PubMed Web of Science ®Google Scholar
• Wang B, Huang Y. Which type of cancer patients are more susceptible to the SARS-COX-2: evidence from a meta-analysis and bioinformatics analysis. Crit Rev Oncol Hematol. 2020;153:103032. doi:10.1016/j.critrevonc.2020.103032.
   PubMed Web of Science ®Google Scholar
• Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21(4):e180. doi:10.1016/S1470-2045(20)30150-9.
   PubMedGoogle Scholar
• Desouky E. BCG versus COVID-19: impact on urology. World J Urol. 2021;39(3):823–827. doi:10.1007/s00345-020-03251-7.
   PubMed Web of Science ®Google Scholar
• Socarrás MR, Loeb S, Teoh JY-C, Ribal MJ, Bloemberg J, Catto J, et al. Telemedicine and smart working: recommendations of the European Association of Urology. European Urology. 2020;78(6):812–819.
   PubMed Web of Science ®Google Scholar
• Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69(2):300–310. doi:10.1016/j.eururo.2015.08.037.
   PubMed Web of Science ®Google Scholar
• Esperto F, Pang KH, Albisinni S, Papalia R, Scarpa RM. Bladder cancer at the time of COVID-19 outbreak. Int Braz J Urol. 2020;46(suppl.1):62–68. doi:10.1590/S1677-5538.IBJU.2020.S107.
   PubMedGoogle Scholar
• Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017;119(3):371–380. doi:10.1111/bju.13760.
   PubMed Web of Science ®Google Scholar
• Au S, Keyes M, Black P, Villamil CF, Tavassoli P. Clinical and pathological characteristics of bladder cancer in post brachytherapy patients. Pathol Res Pract. 2020;216(3):152822. doi:10.1016/j.prp.2020.152822.
   PubMed Web of Science ®Google Scholar
• Farling KB. Bladder cancer: Risk factors, diagnosis, and management. Nurse Pract. 2017;42(3):26–33. doi:10.1097/01.NPR.0000512251.61454.5c.
   PubMed Web of Science ®Google Scholar
• Bellmunt J. Bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):xiii–xiv. doi:10.1016/j.hoc.2014.12.001.
   PubMedGoogle Scholar
• Marzouka NA, Eriksson P, Rovira C, Liedberg F, Sjödahl G, Höglund M. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018;8(1):3737. doi:10.1038/s41598-018-22126-x.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–461. doi:10.1016/j.eururo.2016.05.041.
   PubMed Web of Science ®Google Scholar
• MalekZadeh K, Nikbakht M, Sadeghi IA, Singh SK, Sobti RC. Overexpression of IL-13 in patients with bladder cancer. Cancer Invest. 2010;28(2):201–207. doi:10.3109/07357900903181977.
   PubMed Web of Science ®Google Scholar
• Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol. 2020;78(6):893–906. doi:10.1016/j.eururo.2020.09.006.
   PubMed Web of Science ®Google Scholar
• Samanic CM, Kogevinas M, Silverman DT, Tardon A, Serra C, Malats N, et al. Occupation and bladder cancer in a hospital-based case–control study in Spain. Occup Environ Med. 2008;65(5):347–53. doi:10.1136/oem.2007.035816.
   PubMed Web of Science ®Google Scholar
• Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control. 2000;7(4):325–34. doi:10.1177/107327480000700401.
   PubMedGoogle Scholar
• Huang Z, Wang X, Ma L, Guo Z, Liu H, Du M, et al. Genetic variations in Hippo pathway genes influence bladder cancer risk in a Chinese population. Arch Toxicol. 2020;94(3):785–794. doi:10.1007/s00204-020-02663-z.
   PubMed Web of Science ®Google Scholar
• Ghasemi H, Mousavibahar SH, Hashemnia M, Karimi J, Khodadadi I, Tavilani H. Transitional cell carcinoma matrix stiffness regulates the osteopontin and YAP expression in recurrent patients. Mol Biol Rep. 2021;48(5):4253–4262. doi:10.1007/s11033-021-06440-8.
   PubMed Web of Science ®Google Scholar
• Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, et al. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. 2009;30(12):2047–52. doi:10.1093/carcin/bgp258.
   PubMed Web of Science ®Google Scholar
• Ghasemi H, Mousavibahar SH, Hashemnia M, Karimi J, Khodadadi I, Mirzaei F, et al. Tissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resection. Ann N Y Acad Sci. 2020;1473(1):48–61. doi:10.1111/nyas.14358.
   PubMed Web of Science ®Google Scholar
• Pierzynski JA, Hildebrandt MA, Kamat AM, Lin J, Ye Y, Dinney CP, et al. Genetic variants in the Wnt/β-catenin signaling pathway as indicators of bladder cancer risk. J Urol. 2015;194(6):1771–6. doi:10.1016/j.juro.2015.07.032.
   PubMed Web of Science ®Google Scholar
• Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 2005;65(16):7081–5. doi:10.1158/0008-5472.CAN-05-0267.
   PubMed Web of Science ®Google Scholar
• Tuna B, Yörükoğlu K, Tüzel E, Güray M, Mungan U, Kirkali Z. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract. 2003;199(5):323–8. doi:10.1078/0344-0338-00424.
   PubMed Web of Science ®Google Scholar
• Badawi AF, Habib SL, Mohammed MA, Abadi AA, Michael MS. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest. 2002;20(5-6):651–6. doi:10.1081/cnv-120002490.
   PubMed Web of Science ®Google Scholar
• Zhang Y. Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013;31(4):287–304. doi:10.1080/10590501.2013.844755.
   PubMed Web of Science ®Google Scholar
• Buckley DB, Klaassen CD. Tissue-and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab Dispos. 2007;35(1):121–7. doi:10.1124/dmd.106.012070.
   PubMed Web of Science ®Google Scholar
• Daugherty SE, Lacey JV, Jr Pfeiffer RM, Park Y, Hoover RN, Silverman DT. Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH‐AARP Diet and Health Study. Int J Cancer. 2013;133(2):462–72. doi:10.1002/ijc.28022.
   PubMed Web of Science ®Google Scholar
• McGrath M, Michaud DS, De Vivo I. De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol. 2006;163(3):236–44. doi:10.1093/aje/kwj028.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ, Tindall DJ. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer. 2009;16(1):123–37. doi:10.1677/ERC-08-0124.
   PubMed Web of Science ®Google Scholar
• Chen C-C, Huang C-P, Tsai Y-T, Hseih T-F, Shyr C-R. The genomic alterations of 5α-reductases and their inhibitor finasteride’s effect in bladder cancer. Anticancer Res. 2017;37(12):6893–6898.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99(7):558–68. doi:10.1093/jnci/djk113.
   PubMed Web of Science ®Google Scholar
• Kim A, Kim MS, Ahn J-H, Choi WS, Park HK, Kim HG, et al. Clinical significance of 5-α reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review. Aging Male. 2020;23(5):971–978. doi:10.1080/13685538.2019.1646238.
   PubMed Web of Science ®Google Scholar
• Chen F, Langenstroer P, Zhang G, Iwamoto Y, See WA. Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. J Urol. 2003;170(5):2009–13. doi:10.1097/01.ju.0000092238.15685.10.
   PubMed Web of Science ®Google Scholar
• Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, et al. Expression of estrogen receptors‐α and‐β in bladder cancer cell lines and human bladder tumor tissue. Cancer Interdiscipl Inter J Am Cancer Soc. 2006;106(12):2610–6. doi:10.1002/cncr.21945.
   Google Scholar
• Teoh JY, Roupret M, Shariat SF, Herrmann T. Intravesical therapy for bladder cancer in the pandemic of Covid-19. World J Urol. 2021;39(4):1313–1314. doi:10.1007/s00345-020-03218-8.
   PubMed Web of Science ®Google Scholar
• Lieberman-Cribbin W, Galsky M, Casey M, Liu B, Oh W, Flores R, et al. Hospital centralization impacts high-risk lung and bladder cancer surgical patients. Cancer Invest. 2017;35(10):652–661. doi:10.1080/07357907.2017.1406495.
   PubMed Web of Science ®Google Scholar
• Barresi V, Ieni A, Magno C, Barresi G. High-grade urothelial carcinoma of the urinary bladder showing acquisition of microcystic histology in the penile metastasis: histogenetic considerations. Pathol Res Pract. 2009;205(8):568–71. doi:10.1016/j.prp.2008.12.005.
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Malkowicz SB. Recent advances in bladder cancer chemotherapy. Cancer Invest. 2001;19(1):77–85. doi:10.1081/cnv-100000078.
   PubMed Web of Science ®Google Scholar
• Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–56. doi:10.1016/j.eururo.2009.04.038.
   PubMed Web of Science ®Google Scholar
• Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209–16. doi:10.1046/j.1464-410x.2001.02306.x.
   PubMed Web of Science ®Google Scholar
• Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216–23. doi:10.1016/j.urology.2005.12.014.
   PubMed Web of Science ®Google Scholar
• Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485–90. doi:10.1111/j.1464-410x.2003.04655.x.
   PubMed Web of Science ®Google Scholar
• Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–5. doi:10.1097/01.ju.0000039680.90768.b3.
   PubMed Web of Science ®Google Scholar
• Murali-Krishnan S, Pang KH, Greco F, Fiori C, Catto JW, Vavassori VL, EAU-ESRU (European Associations of Urology-European Society of Residents Urologist), et al. Bladder-sparing treatment in MIBC: where do we stand? Minerva Urol Nefrol. 2019;71(2):101–112. doi:10.23736/S0393-2249.19.03317-4.
   PubMed Web of Science ®Google Scholar
• Ribal MJ, Cornford P, Briganti A, Knoll T, Gravas S, Babjuk M, et al. European association of urology guidelines office rapid reaction group: an organisation-wide collaborative effort to adapt the european association of urology guidelines recommendations to the coronavirus disease 2019 Era. Eur Urol. 2020;78(1):21–28. doi:10.1016/j.eururo.2020.04.056.
   PubMed Web of Science ®Google Scholar
• Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, et al. Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic. Eur Urol. 2020;78(1):29–42. doi:10.1016/j.eururo.2020.04.063.
   PubMed Web of Science ®Google Scholar
• Marco-Franco JE, Guadalajara-Olmeda N, González-de Julián S, Vivas-Consuelo D. COVID-19 healthcare planning: predicting mortality and the role of the herd immunity barrier in the general population. Sustainability. 2020;12(13):5228. doi:10.3390/su12135228.
   Web of Science ®Google Scholar
• Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–795. doi:10.1016/j.eururo.2018.09.001.
   PubMed Web of Science ®Google Scholar
• Krajewski W, Moschini M, Chorbińska J, Nowak Ł, Poletajew S, Tukiendorf A, European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group, et al. Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes. World J Urol. 2021;39(7):2545–2552. doi:10.1007/s00345-020-03522-3.
   PubMed Web of Science ®Google Scholar
• Bhat A, Kwon D, Soodana-Prakash N, Mouzannar A, Punnen S, Gonzalgo ML, et al. Surveillance intensity in intermediate risk, nonmuscle invasive bladder cancer: revisiting the optimal timing and frequency of cystoscopy. J Urol. 2021;206(1):22–28. 0000000000001689. doi:10.1097/JU.
   PubMed Web of Science ®Google Scholar
• Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087. doi:10.1136/bmj.m4087.
   PubMed Web of Science ®Google Scholar
• Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–72. doi:10.1016/j.eururo.2012.10.039.
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol. 2014;11(3):153–62. doi:10.1038/nrurol.2014.15.
   PubMed Web of Science ®Google Scholar
• Rouprêt M, Neuzillet Y, Masson-Lecomte A, Colin P, Compérat E, Dubosq F, et al. CCAFU french national guidelines 2016-2018 on bladder cancer]. Progres en Urologie: journal de L'Association Francaise D'urologie et de la Societe Francaise D'urologie. 2016;27:S67–s91. [ doi:10.1016/S1166-7087(16)30704-7.
   PubMedGoogle Scholar
• Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615–625. doi:10.1038/s41585-018-0055-4.
   PubMed Web of Science ®Google Scholar
• Numakura S, Morikawa T, Ushiku T, Toyoshima T, Fukayama M. Langerhans cell histiocytosis of the urinary bladder in a patient with bladder cancer previously treated with intravesical Bacillus Calmette–Guérin therapy. Pathol Res Pract. 2014;210(2):123–6. doi:10.1016/j.prp.2013.11.005.
   PubMed Web of Science ®Google Scholar
• Ashton A, Murthy Kusuma VR, Crew J, Mostafid AH. BCG therapy in NMIBC: how much and for how long? Arch Esp Urol. 2018;71(4):342–348.
   PubMed Web of Science ®Google Scholar
• Tomisaki I, Kubo T, Minato A, Fujimoto N. Efficacy and tolerability of bacillus calmette-guérin therapy as the first-line therapy for upper urinary tract carcinoma in situ. Cancer Invest. 2018;36(2):152–157. doi:10.1080/07357907.2018.1430815.
   PubMed Web of Science ®Google Scholar
• Liu K, Zhao K, Wang L, Sun E. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer. Pathol Res Pract. 2018;214(8):1074–1080. doi:10.1016/j.prp.2018.05.010.
   PubMed Web of Science ®Google Scholar
• Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol. 2015;7:65–79.
   PubMed Web of Science ®Google Scholar
• Zhu J, Yuan Y, Wan X, Yin D, Li R, Chen W, et al. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 2021;12(12):Cd011300. doi:10.1002/14651858.CD011300.pub2.
   PubMedGoogle Scholar
• Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer. 2001;92(5):697–702. doi:10.1002/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z.
   PubMed Web of Science ®Google Scholar
• Ghasemi H, Amini MA, Pegah A, Azizi E, Tayebinia H, Khanverdilou S, et al. Overexpression of reactive oxygen species modulator 1 is associated with advanced grades of bladder cancer. Mol Biol Rep. 2020;47(9):6497–6505. doi:10.1007/s11033-020-05702-1.
   PubMed Web of Science ®Google Scholar
• Hegarty PK, Sfakianos JP, Giannarini G, DiNardo AR, Kamat AM. COVID-19 and bacillus Calmette-Guérin: what is the link? Eur Urol Oncol. 2020;3(3):259–261. doi:10.1016/j.euo.2020.04.001.
   PubMed Web of Science ®Google Scholar
• Koti M, Morales A, Graham CH, Siemens DR. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy. J Immunother Cancer. 2020;8(2):e001119. doi:10.1136/jitc-2020-001119.
   PubMed Web of Science ®Google Scholar
• Hegarty PK, Kamat AM, Zafirakis H, Dinardo A. BCG vaccination may be protective against Covid-19. 2020.
   Google Scholar
• Roshanravan N, Seif F, Ostadrahimi A, Pouraghaei M, Ghaffari S. Targeting cytokine storm to manage patients with COVID-19: a mini-review. Arch Med Res. 2020;51(7):608–612. doi:10.1016/j.arcmed.2020.06.012.
   PubMed Web of Science ®Google Scholar
• Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care providers and the protection against COVID-19. J Clin Invest. 2021;131(2):e145545. doi:10.1172/JCI145545.
   PubMed Web of Science ®Google Scholar
• https://www.urotoday.com/library-resources/bladder-cancer/120412-beyond-bladder-cancer-bacillus-calmette-guerin-bcgvaccination-revisited-as-a-strategy-to-reduce-covid-19-hospitalization-in-the-elderly.html?pk_campaign=KamatSocialLibResource_120412
   Google Scholar
• Tully KH, Cole AP, Krimphove MJ, Friedlander DF, Mossanen M, Herzog P, et al. Contemporary treatment patterns for non-muscle-invasive bladder cancer: has the use of radical cystectomy changed in the BCG shortage era? Urology. 2021;147:199–204. doi:10.1016/j.urology.2020.08.004.
   PubMed Web of Science ®Google Scholar
• https://www.auanet.org/about-us/bcg-shortage-info
   Google Scholar